Vnitr Lek 2005, 51(1):115-118

Bioekvivalenční studie s novými antihypertenzivy

T. Doležal, T. Hauser
Ústav farmakologie 3. LF UK
Korporátní oddělení klinických studií a vývoje, Zentiva, a.s.

Published: January 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležal T, Hauser T. Bioekvivalenční studie s novými antihypertenzivy. Vnitr Lek. 2005;51(1):115-118.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shargel L, Yu Andrew. Bioavailability and bioequivalence. In: Applied Biopharmaceutics and Pharmacokinetics. 4th edition. Appleton Lange1999: 247-279.
    2. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-680. Go to original source... Go to PubMed...
    3. Westlake WJ. Response to Kirkwood, TBL.: Bioequivalence testing - a need to rethink. Biometrics 1981; 37: 589-594. Go to original source...
    4. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville MD 20857, March 2003.
    5. Committee for Proprietary Medicinal Products (CPMP), the European Agency for the Evaluation of Medicinal Products (EMEA). Note for Guidance on the Investigation of Bioavailability and Bioequivalence. 2001.
    6. Boddy AW, Snikeris FC, Kringle RO, Wei GCG, Oppermann JA, Midha KK. An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs. Pharm. Res. 1995; 12: 1865-1868. Go to original source... Go to PubMed...
    7. Pharmakl report. A two-way, randomized, single-dose, cross-over, balanced, fasted study of amlodipin 10 tablets in normal male volunteers. Prague: Pharmakl 1999.
    8. Cepha report. A single dose, randomized, two period, two-treatment, two sequence, crossover bioequivalence study on ramipril 5 mg tablets versus Delix® 5 mg tablets (Hoechst AG) in healthy volunteers. Pilsen: Cepha 2002.
    9. VULM report. Bioequivalence study with two preparations containing betaxolol hydrochlorid Betaxolol-20 SL and Kerlone® 20 mg tbl. (Synthelabo) after single dose to healthy volunteers. Modra: VULM 2002.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.